Live

China retaliated to President Trump's tariffs with 34% duties on US goods. See the latest.

NasdaqGS - Nasdaq Real Time Price USD

Upstream Bio, Inc. (UPB)

6.30

-0.19

(-2.93%)

At close: April 3 at 4:00:00 PM EDT

6.40

+0.10

+(1.59%)

Pre-Market: 8:06:31 AM EDT

Upstream Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights

– Completed enrollment of Phase 2 clinical trial of verekitug in patients with chronic rhinosinusitis with nasal polyps; top-line data expected in the second half of 2025 – – Completed upsized IPO with gross proceeds of approximately $293 million, extending runway through 2027 – WALTHAM, Mass., March 12, 2025 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (Nasdaq: UPB), a clinical-stage company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders, today

GlobeNewswire 23 days ago

UPB
-2.93%
Upstream Bio to Present at Upcoming March Investor Conferences

WALTHAM, Mass., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (Nasdaq: UPB), a clinical-stage company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders, today announced that Rand Sutherland, MD, Upstream Bio’s CEO, will present at the following upcoming March investor conferences: TD Cowen 45th Annual Health Care Conference, Boston MATuesday, March 4, 2025, 11:50 a.m. – 12:20 p.m. ET Leerink Partners Global Biopharma Conference 2025, Mi

GlobeNewswire last month

UPB
-2.93%
Automotive Security Leaders Must Take Immediate Action to Mitigate the Surging Cyber Threats--Upstream Report Reveals Critical Gaps

Upstream Security, the leading provider of cloud-based cybersecurity and data management platform purpose-built for automotive, smart mobility, and IoT ecosystem, today released the 2025 Automotive & Smart Mobility Cybersecurity Report. The annual report, returning for its seventh year, highlights that despite the increased regulatory attention, the number, scale, and severity of cyber attacks continues to grow, showing a false sense of security and resilience. Automakers and mobility stakeholde

PR Newswire last month

UPB
-2.93%
Upstream Bio to Present at the 43rd Annual J.P. Morgan Healthcare Conference

WALTHAM, Mass., Jan. 06, 2025 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (Nasdaq: UPB), a clinical-stage company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders, today announced that Rand Sutherland, MD, MPH, Upstream Bio’s CEO, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2025 at 2:15 p.m. PT. A live webcast of the presentation will be available under the “Events” tab on the “Investors” page of the Co

GlobeNewswire 2 months ago

UPB
-2.93%
Upstream Bio Appoints Allison Ambrose as General Counsel

WALTHAM, Mass., Dec. 17, 2024 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (Nasdaq: UPB), a clinical-stage company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders, today announced that the Company has appointed Allison Ambrose, J.D. as General Counsel. Ms. Ambrose is a senior legal leader with more than 15 years of experience providing counsel on a wide range of matters including corporate governance, securities law and compliance, and capital mar

GlobeNewswire 3 months ago

UPB
-2.93%
Upstream Bio Announces Addition to Russell 2000® Index

WALTHAM, Mass., Dec. 16, 2024 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (Nasdaq: UPB), a clinical-stage company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders, today announced that the Company will be added to the Russell 2000® index as part of the planned fourth quarter initial public offering (IPO) additions effective at the open of the U.S. equity markets on December 23, 2024. Russell indexes are widely used by investment managers and insti

GlobeNewswire 3 months ago

UPB
-2.93%
Upstream Bio to Participate in the Piper Sandler 36th Annual Healthcare Conference

WALTHAM, Mass., Nov. 21, 2024 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (Nasdaq: UPB), a clinical-stage company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders, today announced that Rand Sutherland, MD, MPH, Upstream Bio’s CEO, will participate in a fireside chat at the Piper Sandler 36th Annual Healthcare Conference on December 3, 2024 at 2:00 p.m. ET. A live webcast of the presentation will be available under the “Events” tab on the “Investor

GlobeNewswire 4 months ago

UPB
-2.93%
Upstream Bio reports Q3 revenue $607,000 vs $621,000 last year

“At Upstream Bio (UPB), we continue to make significant progress toward developing verekitug, the only monoclonal antibody currently in clinical development that targets and inhibits the thymic stromal lymphopoietin receptor, in severe respiratory diseases with substantial unmet needs. We expect to report top-line data from our ongoing Phase 2 clinical trials in severe asthma and chronic rhinosinusitis with nasal polyps in the second half of 2026 and the second half of 2025, respectively. In add

TipRanks 4 months ago

UPB
-2.93%
Upstream Bio Reports Third Quarter 2024 Financial Results and Recent Business Highlights

– Advancing Phase 2 clinical trials of verekitug in patients with severe asthma and CRSwNP – – Commenced startup for a Phase 2 clinical trial in COPD; on track for first patient to be dosed in H2 2025 – – Completed upsized IPO with gross proceeds of approximately $293 million, extending runway through 2027 – WALTHAM, Mass., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (Nasdaq: UPB), a clinical-stage company developing treatments for inflammatory diseases, with an initial focus on severe

GlobeNewswire 4 months ago

UPB
-2.93%
Orbimed Advisors LLC Acquires New Stake in Upstream Bio Inc

On October 15, 2024, Orbimed Advisors LLC, a prominent investment firm, executed a significant transaction by purchasing 4,554,873 shares of Upstream Bio Inc (NASDAQ:UPB), a clinical-stage biotechnology company. This purchase marks a new holding for the firm, with the shares acquired at a price of $23 each, reflecting a strategic move in the biotechnology sector. Founded in 1989, Orbimed Advisors LLC has grown from a public equity fund to a global leader in healthcare investment, managing approximately $15 billion across various funds.

GuruFocus.com 5 months ago

UPB
-2.93%
Upstream Bio Announces Closing of $293 Million Upsized Initial Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

WALTHAM, Mass., Oct. 15, 2024 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (Nasdaq: UPB), a clinical-stage biotechnology company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders, today announced the closing of its upsized initial public offering of 17,250,000 shares of its common stock at a public offering price of $17.00 per share, which includes 2,250,000 shares issued upon the full exercise by the underwriters of their option to purchase additio

GlobeNewswire 5 months ago

UPB
-2.93%
Opening Day: Another trio of biotech IPOs make Friday debut

The Partners Group-backed KinderCare sold 24 million shares for $24 each this Tuesday. At the IPO price, the childhood education company had a market value of $2.74B, based on the outstanding shares. Sky Quarry, Click Holdings, and SKK Holdings also opened for trading this week. Meanwhile, a new trio of biotech companies’ shares came to market on Friday as Upstream Bio, Ceribell and Camp4 Therapeutics each made their public debut. In mid-September, Bicara Therapeutics (BCAX), MBX Biosciences (MB

TipRanks 5 months ago

C

CBLL
-2.65%
ZBIO
-7.47%
Upstream Bio Announces Pricing of Upsized Initial Public Offering

WALTHAM, Mass., Oct. 10, 2024 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (Nasdaq: UPB), a clinical-stage biotechnology company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders, today announced the pricing of its upsized initial public offering of 15,000,000 shares of its common stock at a public offering price of $17.00 per share. All of the shares of common stock are being offered by Upstream. Upstream’s shares are expected to begin trading on t

GlobeNewswire 5 months ago

UPB
-2.93%